SAN DIEGO, Aug. 28 Cadence Pharmaceuticals, Inc.(Nasdaq: CADX) announced today the appointments of Todd Rich, M.D. to thecompany's board of directors and Malcolm Lloyd-Smith to the position of SeniorVice President, Regulatory Affairs and Quality Assurance. Mr. Lloyd-Smithassumes the role previously held by Malvina Laudicina, who resigned from thecompany for medical reasons.
"We are very pleased to welcome Dr. Rich to our board of directors,"stated Cam Garner, Chairman of Cadence. "Todd brings to Cadence a wealth ofclinical development, regulatory, and general management expertise, which willbe invaluable as we continue to build a world class, hospital-focusedbiopharmaceutical company."
"Malcolm's extensive regulatory and quality assurance experience is agreat asset to Cadence," added James Breitmeyer, M.D., Ph.D., Executive VicePresident and Chief Medical Officer of Cadence. "Malcolm will play a key rolein helping us achieve our regulatory objectives for our two Phase III productcandidates, Acetavance(TM) for the treatment of acute pain and fever, andOmigard(TM) for the prevention of catheter-related infections."
Dr. Rich is currently Vice President, Development Regulatory, MedicalInformation, Drug Safety, Quality and Compliance at Genentech, Inc. Dr. Richjoined Genentech in 1992 and has served in a variety of roles, including VicePresident, Clinical and Commercial Regulatory Affairs and Senior Director,Product Development, where he was the Global Project Team Leader forRituxan(R) (rituximab). Previously, he was a Staff Physician at St. John'sHospital in Detroit, Michigan. Dr. Rich received his B.S. in biology fromAmherst College and his M.S. in biomedical engineering from the University ofMichigan. He holds an M.D. from Wayne State University and an M.B.A. from theStanford University Graduate School of Business.
Mr. Lloyd-Smith joins Cadence from Elan Pharmaceuticals, Inc., where hewas most recently Vice President and Head of Global Regulatory Affairs, andwhere he led the successful filings and approvals of Tysabri(R) (natalizumab)and Prialt(R) (ziconotide) in the United States and Europe. At Elan, he wasresponsible for the development and implementation of global regulatorystrategy for all research and development and commercialization activities,as well as the global management of the pharmacovigilance and medical writingfunctions. Previously, Mr. Lloyd-Smith held senior regulatory positions withBristol-Myers Squibb Pharmaceuticals and its predecessor, DuPontPharmaceuticals, where he was most recently Vice President, WorldwideRegulatory Affairs. He received his M.S. in pharmacological biochemistry fromHatfield Polytechnic and his B.S. in pharmacology from the University ofLeeds.
About Cadence Pharmaceuticals, Inc.
Cadence Pharmaceuticals is a biopharmaceutical company focused onin-licensing, developing and commercializing proprietary product candidatesprincipally for use in the hospital setting. The company currently has twoPhase III product candidates in development, Acetavance(TM) (intravenousacetaminophen) for the treatment of acute pain and fever, and Omigard(TM)(omiganan pentahydrochloride 1% topical gel) for the prevention ofcatheter-related infections. For more information about Cadence's pipeline,visit http://www.cadencepharm.com.
Statements included in this press release that are not a description ofhistorical facts are forward-looking statements. Words such as "will,""believe," and similar expressions, are intended to identify forward-lookingstatements, and are based on Cadence's current beliefs and expectations.Forward-looking statements include statements regarding the company'sexpectations that it will build a world-class biopharmaceutical company andachieve regulatory objectives for its product candidates. The inclusion offorward-looking statements shou